The report offers an in-depth analysis of the emerging and current trends, market size, future estimations, and key players.
For Right Perspective and Competitive Insights, Get Sample Report at: https://www.alliedmarketresearch.com/request-sample/3612
Factors such as surge in worldwide prevalence of narcolepsy, increase in the number of narcolepsy awareness services and programs, and presence of reimbursement policies regarding narcolepsy propel the global narcolepsy drugs market. On the other hand, factors including hazardous effects and risks associated with narcolepsy drugs and delayed diagnosis or wrong diagnosis are expected to hinder the market growth. Untapped markets in developing countries are the best opportunity for the market players.
Covid-19 impact on global narcolepsy drugs market:
Covid-19 is a lethal pandemic on which there is a lack of appropriate treatment available. Hence the focus on drugs and medical equipment manufacturers is on developing solutions needed for the treatment of Covid-19. This is keeping the narcolepsy drugs market on the back burner.
The pandemic has affected the supply chain network across the globe and research activities are also affected due to the lack of a workforce.
The report segments the global narcolepsy drugs market on the basis of disease type, therapeutic type, and region.
Based on disease type, the daytime extreme sleepiness segment accounted for the largest market share in 2020, contributing to nearly half of the total share, and is expected to maintain the lead throughout the forecast period. On the other hand, the cataplexia segment is estimated to witness the fastest CAGR of 10.0% from 2021 to 2030.
Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert: https://www.alliedmarketresearch.com/purchase-enquiry/3612
Based on the therapeutic type, the sodium oxybate segment contributed to the largest share in 2020, accounting for more than three-fifths of the global narcolepsy drugs market. The same segment is expected to lead throughout the forecast period. However, the selective serotonin reuptake inhibitor segment is expected to manifest the highest CAGR of 10.9% from 2021 to 2030.
Based on region, North America contributed to the highest share in 2020, holding more than two-thirds of the total share, and is expected to maintain dominance throughout the forecast period. On the other hand, Asia-Pacific is expected to portray the fastest CAGR of 11.6% during the forecast period.
Leading players of the global narcolepsy drugs market analyzed in the research include Bioprojet Company, Ligand Pharmaceuticals Incorporated, Graymark Healthcare, Inc., Arena Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Jazz Pharmaceuticals plc, Takeda Pharmaceutical Company Limited, Shionogi Inc., Novartis International AG, and Teva Pharmaceutical Industries Limited.
